Table 2.

Clinical details of screen detected lung cancers

T0 outcome	Stage	VDT (days)	Final stage	Pathology (subtype)	Treatment
Indeterminate	pT1a N0	369	IA	Adenocarcinoma (acinar)	Surgery
Indeterminate	pT1a N0	148	IA	Adenocarcinoma (acinar)	Surgery
Indeterminate	pT1a N0	89	IA	Squamous	Surgery
Indeterminate	pT1a N0	687*	IA	Adenocarcinoma (acinar 50%, solid 20%, lepidic 30%)	Surgery
Indeterminate	pT1a N0	206	IA	Squamous	Surgery
Indeterminate	pT1a N0	285	IA	Adenocarcinoma (micropapillary 50%, papillary 10%, lepidic 40%)	Surgery
Negative†	pT1a N0	142	IA	Adenocarcinoma (solid 80%, acinar 20%)	Surgery
Negative	cT1a N0	29‡	IA	Clinical	SABR
Negative†	cT1a N0	163	IA	Clinical	SABR
Negative†	cT1a N0	51	IA	NSCLC (NOS)	SABR
Negative	cT1a N0	71§	IA	Squamous	SABR
Negative	cT1a N0	67§	IA	Clinical	No treatment¶
Negative†	cT1b N0	65	IA	Clinical	Radical radiotherapy
Negative	pT2a N0	–	IB	Adenocarcinoma (solid 80%, lepidic 20%)	Surgery
Negative†	cT2a N0	72	IB	NSCLC (NOS)	SABR
Negative	cT1a N2	37‡	IIIA	Squamous	Chemoradiotherapy(S)
Negative	pT1a N2	86§	IIIA	Small cell	Surgery/chemotherapy(A)
Negative	cT4 N2 M1a	34‡	IV	Small cell	Chemoradiotherapy(S)
Negative	cT3 N3 M1b	16‡	IV	Small cell	Chemoradiotherapy(S)

*Morphology of nodule changed with increasing density despite low VDT.

†False negative, ^(S)sequential treatment, ^(A)adjuvant chemotherapy.

‡Estimated VDT.

§VDT calculated between T1 and T1+3-month surveillance scans.

¶Had chemoradiotherapy for oesophageal cancer.

NOS, not otherwise specified; NSCLC, non-small cell lung cancer; SABR, stereotactic ablative radiotherapy; VDT, volume doubling time.